

# EPI Country Report

## BELIZE, 2019



### Demographics and socioeconomic

|  |          |
|--|----------|
| Total Population (in 1000) (2019)                            | 390.35   |
| Population <1 year of age (in 1000) (2019)                   | 7.89     |
| Population 1 year of age (in 1000)(2019)                     | 7.88     |
| Population <5 years of age (in 1000) (2019)                  | 39.32    |
| Women of childbearing age (2019)                             | 214.90   |
| Infant Mortality Rate (per 1000 live births) (2018)          | 12.60    |
| Gross national income (US\$ per capita) current value (2018) | 4,720.00 |
| National Health Expenditure Public (2016)                    | 4.06     |
| National Health Expenditure Private (2016)                   | 1.83     |

### Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- There is no information available on the national technical advisory group on immunization.
- 99% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry is in place.


### Immunization Schedule

| BLZ              | Doses |                         |    |     |     |   |
|------------------|-------|-------------------------|----|-----|-----|---|
|                  | 1     | 2                       | 3  | 4   | 5   | 6 |
| BCG              | B     |                         |    |     |     |   |
| HepB_Pediatric   | B     |                         |    |     |     |   |
| DTP-Hib          |       |                         |    |     |     |   |
| DTP-Hib-HepB     | M2    | M4                      | M6 |     |     |   |
| DTP-Hib-IPV      |       |                         |    |     |     |   |
| DTP-Hib-HepB-IPV |       |                         |    | M18 | Y4  |   |
| DTP              |       |                         |    |     |     |   |
| IPV              | M2    |                         |    |     |     |   |
| OPV              |       | M4                      | M6 | M18 | Y4  |   |
| MMR              | M12   | M18                     |    |     |     |   |
| Pneumoco_conj    |       |                         |    |     |     |   |
| Rotavirus        |       |                         |    |     |     |   |
| Td               |       | Pregnancy first contact |    |     | Y12 |   |
| TdaP             |       |                         |    |     |     |   |
| HPV              |       | Y9                      |    |     |     |   |

### Vaccine Introduction

|                                      | Year |
|--------------------------------------|------|
| Bacterial Meningitis                 |      |
| <i>Haemophilus influenzae</i> type b | 2001 |
| Hepatitis B                          | 2000 |
| HPV                                  | 2016 |
| Influenza                            | 2008 |
| MMR1                                 | 1996 |
| MMR2                                 | 2005 |
| Pentavalent                          | 2002 |
| Pneumococcal Conjugate               |      |
| Rotavirus                            |      |
| Tdap                                 |      |
| Tetraivalent DPT-Hib or DPT-HepB     | 2001 |
| Yellow Fever                         |      |

### Vaccination Coverage



### Surveillance Indicators - AFP (CARPHA)


|   | 2019 |
|---|------|
| Number od AFP suspected cases                 | 8    |
| AFP rate per 100,000 population <15 years old | 0.57 |
| % of cases with 1 adequate samples            | 100  |
| % of cases investigated within <48 hours      | 100  |
| % sites reporting                             | 83   |

### Surveillance Indicators - MR (CARPHA)


|  | 2019 |
|--|------|
| Number of suspected cases                    | 371  |
| % of cases with adequate investigation       | 86   |
| % of cases with adequate blood samples       | 98   |
| % of samples received in laboratory <=5 days | 9    |
| % of laboratory samples results <=4 days     | 83   |




### Polio3 coverage and AFP rate per 100,000 children <15 years of age




### DTP3 coverage and number of reported diphtheria and pertussis cases




### Number of tetanus (no neonatal) and neonatal tetanus cases



### Proportion of municipalities by coverage range with DTP3 in children <1 years of age



### DTP1-DTP3 and DTP1-MMR1 Dropout Rate



**Legend**  
 NB/nb-newborn  
 M/m -month  
 Y/y-year  
 WCBA-women of childbearing age

- with stockout
- no stockout
- no data available

### Vaccine Stockout

